Abstract
Objective To systematically evaluate the effectiveness and safety of valaciclovir (VACV) versus acyclovir (ACV) for the treatment of herpes zoster with Meta-analysis. Methods Databases including the Cochrane library, PubMed, Embase, Medline, SCI, CNKI, Wanfang Data, CBM were searched to collect the randomized controlled trails (RCTs) regarding VACV versus ACV for herpes zoster. The retrieval time was from early available time to May 2016. The search was followed the inclusion and exclusion criteria. The data were collected and evaluated by 2 reviewers independently. The Meta-analysis was conducted using RevMan 5.2 software. Results 13 RCTs involving 1 109 patients were included. The results of Meta-analysis showed that there were significant difference in efficacy, pain relief time, herpes stop time, scab time and PHN between the VACV and ACV groups. Subgroups analysis showed there were no significant difference in efficacy, herpes stop time, scab time between the oral VACV and intravenous ACV subgroups. Conclusion Oral VACV is superior to oral ACV in the treatment of herpes zoster. However there were no differences in herpes stop time, scab time between oral VACV group and intravenous ACV group. Key words: Herpes zoster; Valaciclovir; Aciclovir; Meta-analysis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
